CD69 and acute myeloid leukemia: Building upon these findings, we found that in both pediatric and adult AML patients, LSC and OXPHOS expression signatures are mapped onto HSPC-like leukemic populations and are the two major resistance features. Notably, we identified the adhesion molecule CD69 as a potential biomarker in defining a subpopulation of LSCs that is quiescent and stroma-interacting, and associated with chemoresistance and an increased relapse rate in AML patients.